NDAORALTABLET
Approved
Oct 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EXNA (benzthiazide) is an oral thiazide diuretic tablet approved in 1960 for hypertension and edema management. It works by inhibiting sodium reabsorption in the distal convoluted tubule, reducing blood volume and peripheral resistance. Benzthiazide is a first-generation thiazide used primarily in older patient populations with established cardiovascular and renal indications.
LOE Approaching
Declining franchise with minimal active commercial investment; small, maintenance-focused team managing legacy product.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
FlexNav EU CE Mark Study
Started Feb 2019
46 enrolled
Symptomatic Severe Aortic Stenosis
Career Relevance
Working on EXNA offers limited career growth; this is a legacy maintenance portfolio with minimal innovation or expansion opportunity. Assignment to this product may indicate a support/operational role rather than a strategic career accelerator at Sanofi.
Brand Manager (legacy products)
Worked on EXNA at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.